Off With Their Heads
This article was originally published in Start Up
Executive Summary
A number of recent management shake-ups, in the midst of biotech's deep depression, are an indication of the industry's desperation to find a solution to its stock market woes--as well as the exhaustion of leaders tired of trying to break through Wall Street's attention barriers.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.